Context Therapeutics's market cap is currently ―. The company's EPS TTM is $-1.501; its P/E ratio is -0.94; Context Therapeutics is scheduled to report earnings on May 8, 2024, and the estimated EPS forecast is $-0.45. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
EBIT	$ -6.55M	$ -6.17M	$ -5.30M	$ -6.31M	$ -3.88M
EBITDA	$ -6.32M	-	$ -5.28M	$ -6.28M	$ -3.94M
Net Income Common Stockholders	$ -6.77M	$ -5.87M	$ -5.01M	$ -6.31M	$ -3.56M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 14.40M	$ 21.70M	$ 25.10M	$ 29.80M	$ 35.50M
Total Assets	$ 16.06M	$ 22.99M	$ 27.72M	$ 31.97M	$ 37.97M
Total Debt	$ 0.00	$ 0.00	$ 7.97K	$ 31.67K	$ 55.08K
Net Debt	$ -14.40M	$ -21.70M	$ -25.09M	$ -29.77M	$ -35.44M
Total Liabilities	$ 4.19M	$ 4.60M	$ 3.76M	$ 3.23M	$ 3.21M
Stockholders Equity	$ 11.87M	$ 18.38M	$ 24.01M	$ 28.73M	$ 34.76M
Cash Flow	-
Free Cash Flow	$ -7.23M	-	$ -4.63M	$ -5.73M	$ -3.93M
Operating Cash Flow	$ -7.23M	$ -3.46M	$ -4.63M	$ -5.73M	$ -3.93M
Investing Cash Flow	-	-	-	-	-
Financing Cash Flow	-	-	-	-	-

Currency in USD

Context Therapeutics Earnings and Revenue History

Income Statement >

Context Therapeutics Debt to Assets

Balance Sheet >

Context Therapeutics Cash Flow

Cash Flow >

Context Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing